INK128, a potent and selective TORC1/2 inhibitor, demonstrates anti-tumor activity in preclinical models of renal cell carcinoma by a distinct mechanism

被引：1
|
作者：
Liu, Y. [1 ]
Jessen, K. [1 ]
Wang, S. [1 ]
Kessler, L. [1 ]
Li, L. [1 ]
Darjania, L. [1 ]
Martin, M. [1 ]
Ren, P. [1 ]
Klein, P. [1 ]
Rommel, C. [1 ]
机构：
[1] Intellikine Inc, R&D, La Jolla, CA USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72189-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 155
页数：2
相关论文
共 50 条
  • [1] INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer
    Wang, Shunyou
    Jessen, Katti
    Kessler, Linda
    Kucharski, Jeff
    Lan, Lucy
    Guo, Xin
    Staunton, Jocelyn
    Elia, Marikka
    Stewart, Josh
    Darjania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Mike
    Ren, Pingda
    Rommel, Christian
    Liu, Yi
    CANCER RESEARCH, 2011, 71
  • [2] INK128, a TORC1/2 kinase inhibitor, enhances the efficacy of cytotoxic therapies in endometrial tumor models
    Kessler, Linda
    Jessen, Katti
    Janes, Matthew
    Staunton, Jocelyn
    Kucharski, Jeff
    Guo, Xin
    Elia, Marikka
    Banerjee, Urmi
    Lan, Lucy
    Wang, Shunyou
    Stewart, Josh
    Luzader, Angelina
    Darjania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Michael
    Ren, Pingda
    Rommel, Christian
    Liu, Yi
    CANCER RESEARCH, 2012, 72
  • [3] Preclinical activity of INK128, a TORC1/2 inhibitor, in triple negative breast cancer: A combination of PARP inhibitor with PI3K-mTOR pathway-targeted inhibitor
    Leyland-Jones, Brian
    Wu, Hui
    Sun, Yuliang
    Rommel, Christian
    Yi, Liu
    De, Pradip
    Dey, Nandini
    CANCER RESEARCH, 2012, 72
  • [4] Pre-clinical potency of INK128, a highly potent TORC1/2 kinase inhibitor in the HER2 amplified breast cancer model
    De, Pradip K. R.
    Sun, Yuliang
    Wu, Hui
    Rommel, Christian
    Yi, Liu
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2012, 72
  • [5] Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer
    Wang, Shunyou
    Lan, Lucy
    Janes, Mathew
    Jessen, Katti
    Kessler, Linda
    Kucharski, Jeff
    Guo, Xin Xin
    Staunton, Jocelyn
    Elia, Marikka
    Banerjee, Urmi
    Stewart, Josh
    Dartania, Levan
    Li, Liansheng
    Chan, Katrina
    Martin, Mike
    Ren, Pingda
    Rommei, Christian
    Liu, Yi
    CANCER RESEARCH, 2012, 72
  • [6] Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of glioblastoma
    Piggott, Luke
    Luong, Noemie
    Massiere, Frederic
    Kunze, Annett
    Chardonnens, Christophe
    Vaslin, Anne
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
    Hung Huynh
    Richard Ong
    Khee Chee Soo
    Angiogenesis, 2012, 15 : 59 - 70
  • [8] Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
    Huynh, Hung
    Ong, Richard
    Soo, Khee Chee
    ANGIOGENESIS, 2012, 15 (01) : 59 - 70
  • [9] HMPL-500, a potent and selective EZH1/EZH2 dual inhibitor, demonstrates superior anti-tumor activity in preclinical models of hematological malignancies and solid tumors
    Ge, L.
    Gao, Z.
    Yu, H.
    Xue, W.
    Jiang, A.
    Chen, S.
    Zhang, Y.
    Ding, Q.
    Li, T.
    Wang, J.
    Sai, Y.
    Yang, N.
    Qing, W.
    Ren, Y.
    Su, W.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S98 - S98
  • [10] MLN8054, an Aurora A Kinase inhibitor, demonstrates potent anti-tumor activity in disseminated tumor models
    Zhang, M.
    Meetze, M.
    Huck, J.
    Silva, M.
    Sells, T.
    Claiborne, C.
    Manfredi, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 113 - 113
12345